ScholarLens Back to search
2009•Drug News & PerspectivesRequires access

The role of incretin-based therapies in the management of type 2 diabetes

Prabirkumar Bandyopadhyay

Open publisher page 2 citations

Abstract

Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.

About this research paper

What this paper is about

Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.

Key concepts: Incretin, Type 2 diabetes, Medicine, Diabetes mellitus, Intensive care medicine, Disease, Internal medicine, Endocrinology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
The role of incretin-based therapies in the management of type 2 diabetes — Research Paper | ScholarLens